The Food and Drug Administration (FDA) approved enzalutamide (Xtandi) combined with talazoparib (Talzenna) for certain prostate cancers that have spread to other parts of the body and no longer respond to hormone-blocking treatments. The treatment is for people whose prostate cancer has a change in a specific group of genes involved in repairing damaged DNA.
Treating the rare brain tumor craniopharyngioma often requires surgery, radiation therapy, or both. But the results of a study suggest that combining the targeted therapies vemurafenib (Zelboraf) and cobimetinib (Cotellic) may delay, or even eliminate, the need for these treatments in certain people.
We've added a new drug summary for quizartinib dihydrochloride (Vanflyta), which FDA recently approved to treat adults with newly diagnosed AML that has certain changes in the FLT3 gene.
Information specialists at NCI's Cancer Information Service (CIS), NCI's contact center, can help answer your cancer-related questions in English and Spanish. This page tells you how to reach us by phone, chat, or email.
This email was sent to myhcistech.healthnews360@blogger.com using GovDelivery Communications Cloud on behalf of: National Cancer Institute · BG 9609 MSC 9760 · 9609 Medical Center Drive · Bethesda, MD 20892
No comments:
Post a Comment